Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood.

KaloCyte to participate in DARPA’s Fieldable Solutions for Hemorrhage with bio-
Artificial Resuscitation Products (FSHARP) program, to develop a field-deployable, shelf-stable
whole blood equivalent that can be used to resuscitate trauma patients when donated blood
products are not available.

On October 24, 2022 this year’s David J. Ramsay Entrepreneur of the Year Awards winner Allan Doctor, MD, gave a lecture demonstrating the impact his entrepreneurship and research have had on the community and UMB.

The University of Maryland, Baltimore (UMB) has announced the recipients of their 2022 Founders Week awards in recognition of the extraordinary work of the UMB community, including KaloCyte Co-Founder and Chief Scientific Officer, Allan Doctor, MD

This new book features a full chapter co-authored by KaloCyte’s Research and Development team and serves as a comprehensive and authoritative reference book in blood transfusion and blood substitutes. It is a collection of the latest developments and the newest investigations, and individual chapters are written by world experts in the arena.

ErythroMer™ featured in the August 2022 State of the Art report issued by the Homeland Defense & Security Information Analysis Center (HDIAC)

KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, announced it has closed an investment from New York Blood Center, Inc. (NYBC).